Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Aurinia Pharmaceuticals (AUPH) Misses Q2 EPS by 3c
August 4, 2022 6:09 AM EDTAurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 EPS of ($0.25), $0.03 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $28.2 million versus the consensus estimate of $27.04 million.
GUIDANCE:
Aurinia Pharmaceuticals sees FY2022 revenue of $115-135 million, versus the consensus of... More
